AI-generated research brief — verify at source
MUSKARDIA Shows Non-Significant Cardiovascular Trend in Stable CAD Patients With Reduced Kidney Function
In patients with stable coronary artery disease and reduced kidney function, Shexiang Baoxin pill (MUSKARDIA) did not significantly reduce major adverse cardiovascular events compared to placebo, showing an imprecise roughly 29% lower relative risk that did not reach statistical significance (HR 0.713, 95% CI 0.379–1.342, p=0.292). The wide confidence interval spanning both meaningful benefit and near-null effect indicates the analysis was underpowered, and findings should be interpreted as exploratory rather than conclusive.
What Was Studied
This analysis examined whether MUSKARDIA, a traditional Chinese herbal formulation, could reduce major adverse cardiovascular events in a clinically important but underrepresented subgroup: patients with stable coronary artery disease who also have reduced estimated glomerular filtration rate (eGFR below 90 ml/min/1.73m²). This population is of particular interest because impaired kidney function independently elevates cardiovascular risk, yet patients with renal impairment are frequently excluded or underrepresented in cardiovascular trials.
How It Was Studied
This is a pre-specified subgroup analysis drawn from the MUST trial, a multicenter, double-blind, placebo-controlled phase IV randomized clinical trial (registered as ChiCTR-TRC-12003513). Patients with stable coronary artery disease were originally randomized in a 1:1 ratio to receive MUSKARDIA or matching placebo. For this subgroup analysis, 1,354 participants with a reduced baseline eGFR of less than 90 ml/min/1.73m² were identified and analyzed. The primary composite efficacy endpoint was the incidence of major adverse cardiovascular events, while the secondary composite endpoint encompassed all-cause mortality, non-fatal myocardial infarction, non-fatal stroke, hospitalization for unstable angina or heart failure, and coronary revascularization.
What Was Observed
- The primary composite endpoint of major adverse cardiovascular events showed a numerical but statistically non-significant advantage for MUSKARDIA, representing roughly a 29% lower relative risk compared to placebo, though the estimate was highly imprecise (HR 0.713, 95% CI 0.379–1.342, p=0.292). A directional trend toward protection emerged after 12 months of treatment, but this did not cross the threshold of statistical significance.
- The secondary composite endpoint also favored MUSKARDIA numerically, suggesting approximately a 16% lower relative risk, but this too did not reach statistical significance (HR 0.840, 95% CI 0.608–1.161, p=0.290). Notably, after 14 months of treatment, MUSKARDIA was reported to significantly improve the secondary composite endpoint in time-to-event analyses, suggesting a possible delayed or cumulative therapeutic effect.
- Safety and tolerability profiles were comparable between the MUSKARDIA and placebo groups, with no clinically meaningful differences observed in liver or kidney function indicators across the follow-up period, providing reassurance regarding the use of this herbal preparation in patients with already-impaired renal function.
Why This Matters
Patients with concurrent coronary artery disease and chronic kidney disease represent a high-risk, therapeutically challenging population for whom evidence-based options remain limited. This subgroup analysis provides preliminary, hypothesis-generating data that MUSKARDIA may offer cardiovascular protection in this comorbid group. It also underscores the potential value of rigorously studied traditional Chinese medicines as adjunctive therapies and supports the case for conducting a dedicated, adequately powered trial in this specific population.
How to Read This Result
Given that this is a subgroup analysis with non-significant primary and secondary endpoints, wide confidence intervals, and evident underpowering, the findings are strictly exploratory and cannot support definitive conclusions about efficacy in patients with stable CAD and reduced eGFR.
Limitations
This analysis was conducted as a subgroup of a larger trial rather than as a standalone study, which substantially limits statistical power and the ability to draw causal conclusions. Neither the primary nor the secondary composite endpoint achieved statistical significance, reinforcing that the subgroup was insufficiently sized to detect a reliable treatment effect. The results are therefore hypothesis-generating only and require confirmation through prospective, dedicated randomized trials designed specifically for this patient population.